



文章

获得 6 条结果 (用时0.07秒)

时间不限

2018以来

2017以来

2014以来

自定义范围...

按相关性排序

按日期排序

不限语言

中文网页

简体中文网页

包括专利

包含引用

创建快讯

seek68文献馆--各种中外期刊数据库!

不限IP | 包月下载 | 可开发票 | 九年金牌服务

小提示: 只搜索中文(简体)结果, 可在 学术搜索设置 指定搜索语言

A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties

VK Bhat, BD Kerr, PR Flatt, VA Gault - Biochemical pharmacology, 2013 - Elsevier

... 2.4. cAMP receptor activation. Effects of native GIP, Oxm, dA 2 GIP and dA 2 GIP-Oxm on cAMP production were evaluated in Chinese Hamster Lung (CHL) cells transfected with human GIP [21] or GLP-1 [22] receptors and glucagon receptor transfected HEK293 cells [23] ...

☆ 99 被引用次数: 38 相关文章 所有 7 个版本

NMDAR antagonists for the treatment of diabetes mellitus—Current status and future directions

A Welters, C Klüppel, J Mrugala... - Diabetes, Obesity ..., 2017 - Wiley Online Library

... membrane potentials, and ligand-binding (glutamate or NMDA together with co-agonist glycine or ... Extracellular glutamate activates glutamate receptors and thus influences insulin, glucagon and somatostatin release ... essential role of CREB in mediating the effects of GLP-1 on β ...

☆ 99 被引用次数: 1 相关文章 所有 4 个版本

[PDF] Glucose-dependent insulinotropic polypeptide: Effects on insulin and glucagon secretion in humans

MB Christensen - J Clin Endocrinol Metab, 2014 - pdfs.semanticscholar.org

... that the combination of GIP and GLP-1 (as a single molecule co-agonist) provided greater ... control and improved weight loss of co-agonism compared to either GLP-1 or GIP ... In 2010 we published a paper describing investigations focusing on the glucagon-releasing properties ...

☆ 99 被引用次数: 1 相关文章 所有 5 个版本

[PDF] semanticscholar.org

[引用] Diabetes Risks from Prescription and Nonprescription Drugs: Mechanisms and Approaches to Risk Reduction

Match Overview

Match Number	Match Type	Matched Words	Similarity
1	Crossref	34 words	1%
2	Crossref	13 words	<1%
3	Crossref	12 words	<1%
4	Crossref	11 words	<1%

1 **Crossref** 34 words
 Vishal Patel, Amit Johrapurkar, Samadhan Kshirsagar, Brijesh Sutariya et al. "Coagonist of GLP-1 and glucagon de ..."

2 **Crossref** 13 words
 Vishal Patel, Amit Johrapurkar, Samadhan Kshirsagar, Brijesh Sutariya et al. "Central administration of coagonist o ..."

3 **Crossref** 12 words
 Vishal J Patel, Amit Arvind Johrapurkar, Samadhan Kshirsagar, Maulik S Patel et al. "Coagonist of GLP-1 and gluca ..."

4 **Crossref** 11 words
 "42nd EASD Annual Meeting of the European Association for the Study of Diabetes", Diabetologia, 09/2006

Name of Journal: *World Journal of Diabetes*

Manuscript NO: 39507

Manuscript Type: Original Article

Basic Study

Coagonist of GLP-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus

Vishal J Patel, Amit A Johrapurkar, Samadhan G ²Kshirsagar, Brijesh K Sutariya, Maulik S Patel, Hiren M Patel, Dheerendra K Pandey, Rajesh H Bahekar, Mukul R Jain

Abstract

AIM

This study aims to investigate the role of glucagon-like peptide-1/glucagon receptors

coagonist on renal dysfunction associated with diabetes and obesity.



Coagonist of GLP-1 and glucagon receptors ameliorates kidney injury in m



全部

图片

新闻

视频

购物

更多

设置

工具

找到约 2,300 条结果 (用时 0.76 秒)

Coinfusion of Low-Dose GLP-1 and Glucagon in Man ... - Diabetes

diabetes.diabetesjournals.org/content/63/11/3711 ▾ 翻译此页

作者: J Cegla - 2014 - 被引用次数: 48 - 相关文章

Both glucagon and GLP-1 reduce appetite and cause weight loss. ... The glucagon receptor is expressed in a broad range of tissues, including the liver, kidney, ... are licensed for the treatment of type 2 diabetes, improving glucose control and ... homeostasis in animal models of diet-induced obesity and diabetes (20,21).

[PDF] Problem or solution_ The strange story of glucagon - Semantic Scholar

<https://pdfs.semanticscholar.org/.../e54fcdeb26c90ae432fdbb6d5ff81400bc4...> ▾ 翻译此页

作者: RV Scott - 2018

glucagon appeared to have little significant function in disease, and its clinical use ... from alloxan-induced diabetes in dogs, to patient with type 1 and type 2 diabetes glucagon, GLP-1 and GIP receptors, have been developed, with the aim that the ... that these analogues can reduce body weight in obese mice models.

Problem or solution: The strange story of glucagon - ScienceDirect

<https://www.sciencedirect.com/science/article/pii/S0196978117303595> - 翻译此页

作者: RV Scott - 2018

Glucagon release is inhibited by hyperglycaemia, insulin, GLP-1 and somatostatin [10–12]. ... body, being particularly abundant in the liver, kidney, heart and adipose [13]. ... blood glucose excursions in mice including diabetic models [48–50]. ... of increased cholesterol, type 2 diabetes and cardiovascular disease [60,61,67 ...

Gut hormone polyagonists for the treatment of type 2 diabetes ...

<https://www.sciencedirect.com/science/article/pii/S0196978117303960> - 翻译此页



全部

图片

新闻

视频

购物

更多

设置

工具

找到约 2,000 条结果 (用时 0.77 秒)

Coinfusion of Low-Dose GLP-1 and Glucagon in Man ... - Diabetes

diabetes.diabetesjournals.org/content/63/11/3711 - 翻译此页

作者 : J Cegla - 2014 - 被引用次数 : 48 - 相关文章

Both glucagon and GLP-1 reduce appetite and cause weight loss. ... The glucagon receptor is expressed in a broad range of tissues, including the liver, kidney, ... are licensed for the treatment of type 2 diabetes, improving glucose control and ... homeostasis in animal models of diet-induced obesity and diabetes (20,21).

Problem or solution: The strange story of glucagon - ScienceDirect

<https://www.sciencedirect.com/science/article/pii/S0196978117303595> - 翻译此页

作者 : RV Scott - 2018

Glucagon release is inhibited by hyperglycaemia, insulin, GLP-1 and somatostatin [10–12]. ... body, being particularly abundant in the liver, kidney, heart and adipose [13]. ... blood glucose excursions in mice including diabetic models [48–50]. ... of increased cholesterol, type 2 diabetes and cardiovascular disease [60,61,67 ...

Gut hormone polyagonists for the treatment of type 2 diabetes ...

<https://www.sciencedirect.com/science/article/pii/S0196978117303960> - 翻译此页

作者 : SJ Brandt - 2018

Unimolecular agonists targeting the receptors for GLP-1, GIP and Glucagon offer ... among the best-in-class pharmacotherapies to treat obesity and type 2 diabetes. ... the development and progression of diabetic kidney disease than placebo [43]. ... Interestingly, in DIO mice, the GLP-1/glucagon co-agonist restores leptin ...

Problem or solution: The strange story of glucagon - NCBI - NIH

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805853/> - 翻译此页

作者 : RV Scott - 2018

This rooted glucagon as a central problem in the disease. Glucagon ... Agents developed to block activity at the glucagon receptor to treat diabetes. ... NOX-G15 ameliorates hyperglycaemia in murine models of type 1 and type 2 diabetes. ... Tschop M.H. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.

GLP-1/glucagon receptor co-agonism for treatment of obesity ...

<https://link.springer.com/article/10.1007/s00125-017-4354-8> - 翻译此页

作者 : MA Sánchez-Garrido - 2017 - 被引用次数 : 7 - 相关文章

Over a relatively short period, obesity and type 2 diabetes have come to represent a large function at